Legumain/pH dual-responsive lytic peptide-paclitaxel conjugate for synergistic cancer therapy

• Autors principals: Shanshan Zheng (Autor), Yue Cai (Autor), Yulu Hong (Autor), Yubei Gong (Autor), Licheng Gao (Autor), Qingyong Li (Autor), Le Li (Autor), Xuanrong Sun (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

After molecule targeted drug, monoclonal antibody and antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs) have become the next generation targeted anti-tumor drugs due to its properties of low molecule weight, efficient cell penetration, low immunogenicity, good pharmacokinetic and large...